Daro + ADT 和多西他赛用于 mHSPC：来自 SOGUG 的 TRIDA 研究的真实世界证据 🇪🇸 #ESMO26 @urotoday @Ricardo62949193
mFU：11 个月
📌16.2% 进展为 CRPC
📌mOS NR，18 个月生存概率：86.5%
📌48.5% PSA <= 0.2
📌83.3% 疾病控制
📌安全性与 ARASENS 相似
601 浏览 · 9 赞 · 8 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Zach Klaassen · x.com